Changeflow GovPing Pharma & Drug Safety EPO Patent EP4671270A3: Purifying Low-pI Antibody
Routine Notice Added Final

EPO Patent EP4671270A3: Purifying Low-pI Antibody

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Peptides (C07K)
Published March 18th, 2026
Detected March 23rd, 2026
Email

Summary

The European Patent Office has published patent application EP4671270A3 concerning a method for purifying antibodies with a low isoelectric point. The patent describes techniques to suppress aggregation and improve impurity removal during antibody purification processes.

What changed

This document is a European Patent Office (EPO) publication (EP4671270A3) detailing a method for purifying antibodies with a low isoelectric point. The patent claims an improved purification process that involves removing formed antibody aggregates after Protein A column purification, acidic treatment, and neutralization to suppress further aggregation. It also specifies the use of an anion exchange resin in Bind/Elute mode followed by hydrophobic interaction chromatography or multimodal chromatography for efficient impurity removal, contrasting with conventional methods.

This patent publication is primarily of interest to pharmaceutical and biotechnology companies involved in antibody development and manufacturing. While it does not impose new regulatory obligations, it represents a novel technical approach that may influence future manufacturing processes and intellectual property strategies within the industry. Compliance officers should note this development for its potential impact on R&D and manufacturing best practices.

Source document (simplified)

← EPO Patent Bulletin

METHOD FOR PURIFYING ANTIBODY HAVING LOW ISOELECTRIC POINT

Search Report EP4671270A3 Kind: A3 Mar 18, 2026

Applicants

CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventors

UEDA, Yasufumi, KOBAYASHI, Shohei, YANAGITA, Satoko, KAWASE, Takuo, FUKUNAGA, Masahiro

Abstract

The present inventors discovered that additional aggregation of low-pI antibody can be suppressed by removing formed antibody aggregates after a certain period of time following Protein A column purification, acidic treatment, and neutralization. Furthermore, the present inventors found that efficient impurities removal for a low-pI antibody can be accomplished by using an anion exchange resin in the Bind/Elute mode and then a hydrophobic interaction chromatography or multimodal chromatography resin, compared with conventional methods.

IPC Classifications

C07K 1/22 20060101AFI20260210BHEP A61K 39/395 20060101ALI20260210BHEP C07K 1/18 20060101ALI20260210BHEP C07K 1/20 20060101ALI20260210BHEP C07K 16/00 20060101ALI20260210BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

METHOD FOR PURIFYING ANTIBODY HAVING LOW ISOELECTRIC POINT

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4671270A3

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Antibody Purification
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Intellectual Property Biotechnology

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.